13485-84-2

Basic information

• Product Name: Benzenemethanol, 4-(cyclohexyloxy)-
• CAS NO: 13485-84-2
• Molecular Formula: C13H18O2
• Molecular Weight: 206.285
• Mol File: 13485-84-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 4-(cyclohexyloxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 4-(cyclohexyloxy)-(13485-84-2)
• EPA Substance Registry System: Benzenemethanol, 4-(cyclohexyloxy)-(13485-84-2)

Safety Data

• Hazardous Substances Data: 13485-84-2(Hazardous Substances Data)

Upstream product

• 139-61-7 4-(Cyclohexyloxy)benzoic acid 
• 120-47-8 Ethyl 4-hydroxybenzoate 

Downstream Products

• 1439366-97-8 [4-(cyclohexoxy)-phenyl]methyl N-[(2S,3R)-2-methyl-4-oxo-oxetan-3-yl]-carbamate 
• 1439368-20-3 (2R,3S)-2-[({[4-(cyclohexyloxy)phenyl]methoxy}carbonyl)amino]-3-hydroxybutanoic acid 
• 1439368-18-9 [4-(cyclohexyloxy)phenyl]methyl pyridin-2-yl carbonate 
• 1439368-19-0 [4-(cyclohexyloxy)phenyl]methyl 2-oxo-pyridine-1-carboxylate 

Relevant articles and documents

Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.